← Back

CRC risk by age 40 in UC with vs without PSC

What is the cumulative risk of CRC by age 40 in patients with UC and PSC compared to UC without PSC

FactNot yet clinician-reviewed

What is known

  • In matched UC patients, absolute cumulative risk of colorectal dysplasia/carcinoma in the PSC/UC group was 9%, 31%, and 50% at 10, 20, and 25 years of disease duration. 1
  • In a single-centre retrospective cohort, colorectal dysplasia or cancer developed in patients with ulcerative colitis and PSC (2 cancers and 8 cases of dysplasia over a median follow-up of 11 years), whereas only 1 patient with colonic [Crohn's disease](https://crohnsology.org (patient sites: crohnz.org)/) and PSC developed dysplasia over a median follow-up of 10 years. 2
  • In a large cohort, CRC incidence was 2.9 versus 6.1 per 1,000 person-years for IBD alone versus PSC-IBD from IBD diagnosis (IRR 2.1). 3

What is unknown / caveats

  • Excerpts report cumulative risk by disease duration, not by chronological age 40
  • The age-40 figure requested is not stated in any retrieved excerpt
  • No excerpt provides a cumulative CRC risk indexed to age 40, so the specific number asked for cannot be given from this evidence.

References

  1. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995. PMID: 7590655.
  1. Braden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, Kitiyakara T, Travis SP, Chapman RW. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10(3):303-8. PMID: 22037429.
  1. Trivedi PJ, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J, Hirschfield GM. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020. PMID: 32445859.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.


Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.

Reviewer notes

answered 2026-08-04 · corpus build b46345ef · faithfulness 0.8888888888888888